352 related articles for article (PubMed ID: 27221141)
1. Prescribing Preferences in the First-Line Treatment for Patients With Metastatic Renal Cell Carcinoma in the United States.
Hackshaw MD; Holmes M; Lankford M; Thomas M; Ogbonnaya A; Eaddy M
Clin Genitourin Cancer; 2016 Oct; 14(5):e479-e487. PubMed ID: 27221141
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of pazopanib versus sunitinib for renal cancer in the United States.
Delea TE; Amdahl J; Diaz J; Nakhaipour HR; Hackshaw MD
J Manag Care Spec Pharm; 2015 Jan; 21(1):46-54, 54a-b. PubMed ID: 25562772
[TBL] [Abstract][Full Text] [Related]
3. First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Ruiz-Morales JM; Swierkowski M; Wells JC; Fraccon AP; Pasini F; Donskov F; Bjarnason GA; Lee JL; Sim HW; Sliwczynsk A; Ptak-Chmielewska A; Teter Z; Beuselinck B; Wood LA; Yuasa T; Pezaro C; Rini BI; Szczylik C; Choueiri TK; Heng DY
Eur J Cancer; 2016 Sep; 65():102-8. PubMed ID: 27487293
[TBL] [Abstract][Full Text] [Related]
4. Pazopanib after sunitinib failure in patients with metastatic renal cell carcinoma.
Rautiola J; Utriainen T; Peltola K; Joensuu H; Bono P
Acta Oncol; 2014 Jan; 53(1):113-8. PubMed ID: 23721300
[TBL] [Abstract][Full Text] [Related]
5. Prognostic role of the cumulative toxicity in patients affected by metastatic renal cells carcinoma and treated with first-line tyrosine kinase inhibitors.
Iacovelli R; Verri E; Cossu Rocca M; Aurilio G; Cullurà D; de Cobelli O; Nolè F
Anticancer Drugs; 2017 Feb; 28(2):206-212. PubMed ID: 27754995
[TBL] [Abstract][Full Text] [Related]
6. Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features.
Kim JH; Park I; Lee JL
Cancer Chemother Pharmacol; 2016 Aug; 78(2):325-32. PubMed ID: 27324136
[TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma.
Haaland B; Chopra A; Acharyya S; Fay AP; Lopes Gde L
BMC Cancer; 2014 Aug; 14():592. PubMed ID: 25127891
[TBL] [Abstract][Full Text] [Related]
8. Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis.
Leung HW; Chan AL
Clin Ther; 2011 Jun; 33(6):708-16. PubMed ID: 21704235
[TBL] [Abstract][Full Text] [Related]
9. Treatment patterns: targeted therapies indicated for first-line management of metastatic renal cell carcinoma in a real-world setting.
Hess G; Borker R; Fonseca E
Clin Genitourin Cancer; 2013 Jun; 11(2):161-7. PubMed ID: 23267717
[TBL] [Abstract][Full Text] [Related]
10. Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma.
Iacovelli R; Massari F; Albiges L; Loriot Y; Massard C; Fizazi K; Escudier B
Eur Urol; 2015 Jul; 68(1):154-60. PubMed ID: 25466943
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer.
Iacovelli R; Cossu Rocca M; Galli L; De Giorgi U; Sabbatini R; Santoni M; Mosca A; Fornarini G; Massari F; Masini C; Bersanelli M; Biasco E; Lolli C; Guida A; Berardi R; Terrone C; Pastorino A; Ardizzoni A; Pinto C; Buti S; Nolè F; Tortora G
Urol Oncol; 2017 Sep; 35(9):541.e7-541.e13. PubMed ID: 28572027
[TBL] [Abstract][Full Text] [Related]
12. Assessing Outcomes and Prognostic Factors for First-Line Therapy in Elderly Patients With Metastatic Renal Cell Carcinoma: Real-Life Data From a Single United Kingdom Institution.
Uccello M; Alam T; Abbas H; Nair A; Paskins J; Faust G
Clin Genitourin Cancer; 2019 Jun; 17(3):e658-e663. PubMed ID: 31000484
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.
Xie M; He CS; Huang JK; Lin QZ
Eur J Cancer; 2015 Mar; 51(5):595-603. PubMed ID: 25618828
[TBL] [Abstract][Full Text] [Related]
14. Real-World Effectiveness and Tolerability of Pazopanib as First Targeted Therapy in Metastatic Renal Cell Carcinoma: A Retrospective Chart Review in Latin America.
Queiroz Muniz D; Ratto B; Yang H; Zhao J; Jenkins M; Signorovitch J; Dezzani L; Salman P; Lema Medina M; Lopera D; Lerzo G; Del Castillo C; Chacon M; Martin A; Campos-Gomez S
Adv Ther; 2019 Dec; 36(12):3446-3457. PubMed ID: 31630333
[TBL] [Abstract][Full Text] [Related]
15. Fuhrman Grade and Neutrophil-To-Lymphocyte Ratio Influence on Survival in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors.
Chrom P; Stec R; Semeniuk-Wojtas A; Bodnar L; Spencer NJ; Szczylik C
Clin Genitourin Cancer; 2016 Oct; 14(5):457-464. PubMed ID: 26980234
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of First-Line Targeted Therapy in Real-World Korean Patients with Metastatic Renal Cell Carcinoma: Focus on Sunitinib and Pazopanib.
Kim MS; Chung HS; Hwang EC; Jung SI; Kwon DD; Hwang JE; Bae WK; Park JY; Jeong CW; Kwak C; Song C; Seo SI; Byun SS; Hong SH; Chung J
J Korean Med Sci; 2018 Dec; 33(51):e325. PubMed ID: 30546281
[TBL] [Abstract][Full Text] [Related]
17. Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: a Sarah Cannon Oncology Research Consortium Phase II Trial.
Hainsworth JD; Rubin MS; Arrowsmith ER; Khatcheressian J; Crane EJ; Franco LA
Clin Genitourin Cancer; 2013 Sep; 11(3):270-5. PubMed ID: 23665131
[TBL] [Abstract][Full Text] [Related]
18. Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma.
Bianconi M; Faloppi L; Loretelli C; Zizzi A; Giampieri R; Bittoni A; Andrikou K; Del Prete M; Burattini L; Montironi R; Scartozzi M; Cascinu S
Oncotarget; 2016 Jun; 7(25):37599-37607. PubMed ID: 27175586
[TBL] [Abstract][Full Text] [Related]
19. Effect of the timing of best tumor shrinkage on survival of patients with metastatic renal cell carcinoma who received first-line tyrosine kinase inhibitor therapy.
Ishihara H; Yagisawa T; Kondo T; Omae K; Takagi T; Iizuka J; Kobayashi H; Tanabe K
Int J Clin Oncol; 2017 Feb; 22(1):126-135. PubMed ID: 27549785
[TBL] [Abstract][Full Text] [Related]
20. Variation in use of targeted therapies for metastatic renal cell carcinoma: Results from a Dutch population-based registry.
De Groot S; Sleijfer S; Redekop WK; Oosterwijk E; Haanen JB; Kiemeney LA; Uyl-de Groot CA
BMC Cancer; 2016 Jun; 16():364. PubMed ID: 27286871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
